LENZ Therapeutics, Inc. (NASDAQ:LENZ) will release earnings for its fourth quarter before the opening bell on Tuesday, March 24.

Analysts expect the Solana Beach, California-based company to report quarterly loss of 90 cents per share, versus a year-ago loss of 46 cents per share. The consensus estimate for LENZ Therapeutics' quarterly revenue is $3.09 million, according to Benzinga Pro.

On March 10, LENZ Therapeutics submitted marketing authorization application to EMA for review, approval of VIZZ to treat presbyopia in adults.

Shares of LENZ Therapeutics gained 5% to close at $11.00 on Monday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

  • Raymond James analyst Gary Nachman maintained an Outperform rating and raised the price target from $40 to $50 on Oct. 20, 2025. This analyst has an accuracy rate of 60%.
  • Piper Sandler analyst Biren Amin maintained an Overweight rating and increased the price target from $51 to $67 on Oct. 10, 2025. This analyst has an accuracy rate of 58%.
  • Citigroup analyst Yigal Nochomovitz maintained a Buy rating and raised the price target from $49 to $52 on Aug. 1, 2025. This analyst has an accuracy rate of 57%.
  • HC Wainwright & Co. analyst Matthew Caufield maintained a Buy rating and lifted the price target from $48 to $56 on Aug. 1, 2025. This analyst has an accuracy rate of 72%.

Considering buying LENZ stock? Here’s what analysts think:

Photo via Shutterstock